Cargando…

Left atrial volume and cardiovascular outcomes in systolic heart failure: effect of antithrombotic treatment

AIMS: Left atrium (LA) dilation is associated with adverse cardiovascular (CV) outcomes. Blood stasis, thrombus formation and atrial fibrillation may occur, especially in heart failure (HF) patients. It is not known whether preventive antithrombotic treatment may decrease the incidence of CV events...

Descripción completa

Detalles Bibliográficos
Autores principales: Di Tullio, Marco R., Qian, Min, Thompson, John L.P., Labovitz, Arthur J., Mann, Douglas L., Sacco, Ralph L., Pullicino, Patrick M., Freudenberger, Ronald S., Teerlink, John R., Graham, Susan, Lip, Gregory Y.H., Levin, Bruce, Mohr, Jay P., Buchsbaum, Richard, Estol, Conrado J., Lok, Dirk J., Ponikowski, Piotr, Anker, Stefan D., Homma, Shunichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6165930/
https://www.ncbi.nlm.nih.gov/pubmed/30015405
http://dx.doi.org/10.1002/ehf2.12331
_version_ 1783359935740903424
author Di Tullio, Marco R.
Qian, Min
Thompson, John L.P.
Labovitz, Arthur J.
Mann, Douglas L.
Sacco, Ralph L.
Pullicino, Patrick M.
Freudenberger, Ronald S.
Teerlink, John R.
Graham, Susan
Lip, Gregory Y.H.
Levin, Bruce
Mohr, Jay P.
Buchsbaum, Richard
Estol, Conrado J.
Lok, Dirk J.
Ponikowski, Piotr
Anker, Stefan D.
Homma, Shunichi
author_facet Di Tullio, Marco R.
Qian, Min
Thompson, John L.P.
Labovitz, Arthur J.
Mann, Douglas L.
Sacco, Ralph L.
Pullicino, Patrick M.
Freudenberger, Ronald S.
Teerlink, John R.
Graham, Susan
Lip, Gregory Y.H.
Levin, Bruce
Mohr, Jay P.
Buchsbaum, Richard
Estol, Conrado J.
Lok, Dirk J.
Ponikowski, Piotr
Anker, Stefan D.
Homma, Shunichi
author_sort Di Tullio, Marco R.
collection PubMed
description AIMS: Left atrium (LA) dilation is associated with adverse cardiovascular (CV) outcomes. Blood stasis, thrombus formation and atrial fibrillation may occur, especially in heart failure (HF) patients. It is not known whether preventive antithrombotic treatment may decrease the incidence of CV events in HF patients with LA enlargement. We investigated the relationship between LA enlargement and CV outcomes in HF patients and the effect of different antithrombotic treatments. METHODS AND RESULTS: Two‐dimensional echocardiography with LA volume index (LAVi) measurement was performed in 1148 patients with systolic HF from the Warfarin versus Aspirin in Reduced Ejection Fraction (WARCEF) trial. Patients were randomized to warfarin or aspirin and followed for 3.4 ± 1.7 years. While the primary aim of the trial was a composite of ischaemic stroke, death, and intracerebral haemorrhage, the present report focuses on the individual CV events, whose incidence was compared across different LAVi and treatment subgroups. After adjustment for demographics and clinical covariates, moderate or severe LA enlargement was significantly associated with total death (hazard ratio 1.6 and 2.7, respectively), CV death (HR 1.7 and 3.3), and HF hospitalization (HR 2.3 and 2.6) but not myocardial infarction (HR 1.0 and 1.4) or ischaemic stroke (1.1 and 1.5). The increased risk was observed in both patients treated with warfarin or aspirin. In warfarin‐treated patients, a time in therapeutic range >60% was associated with lower event rates, and an interaction between LAVi and time in therapeutic range was observed for death (P = 0.034). CONCLUSIONS: In patients with systolic HF, moderate or severe LA enlargement is associated with death and HF hospitalization despite treatment with antithrombotic medications. The possibility that achieving a more consistent therapeutic level of anticoagulation may decrease the risk of death requires further investigation.
format Online
Article
Text
id pubmed-6165930
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-61659302018-10-04 Left atrial volume and cardiovascular outcomes in systolic heart failure: effect of antithrombotic treatment Di Tullio, Marco R. Qian, Min Thompson, John L.P. Labovitz, Arthur J. Mann, Douglas L. Sacco, Ralph L. Pullicino, Patrick M. Freudenberger, Ronald S. Teerlink, John R. Graham, Susan Lip, Gregory Y.H. Levin, Bruce Mohr, Jay P. Buchsbaum, Richard Estol, Conrado J. Lok, Dirk J. Ponikowski, Piotr Anker, Stefan D. Homma, Shunichi ESC Heart Fail Original Research Articles AIMS: Left atrium (LA) dilation is associated with adverse cardiovascular (CV) outcomes. Blood stasis, thrombus formation and atrial fibrillation may occur, especially in heart failure (HF) patients. It is not known whether preventive antithrombotic treatment may decrease the incidence of CV events in HF patients with LA enlargement. We investigated the relationship between LA enlargement and CV outcomes in HF patients and the effect of different antithrombotic treatments. METHODS AND RESULTS: Two‐dimensional echocardiography with LA volume index (LAVi) measurement was performed in 1148 patients with systolic HF from the Warfarin versus Aspirin in Reduced Ejection Fraction (WARCEF) trial. Patients were randomized to warfarin or aspirin and followed for 3.4 ± 1.7 years. While the primary aim of the trial was a composite of ischaemic stroke, death, and intracerebral haemorrhage, the present report focuses on the individual CV events, whose incidence was compared across different LAVi and treatment subgroups. After adjustment for demographics and clinical covariates, moderate or severe LA enlargement was significantly associated with total death (hazard ratio 1.6 and 2.7, respectively), CV death (HR 1.7 and 3.3), and HF hospitalization (HR 2.3 and 2.6) but not myocardial infarction (HR 1.0 and 1.4) or ischaemic stroke (1.1 and 1.5). The increased risk was observed in both patients treated with warfarin or aspirin. In warfarin‐treated patients, a time in therapeutic range >60% was associated with lower event rates, and an interaction between LAVi and time in therapeutic range was observed for death (P = 0.034). CONCLUSIONS: In patients with systolic HF, moderate or severe LA enlargement is associated with death and HF hospitalization despite treatment with antithrombotic medications. The possibility that achieving a more consistent therapeutic level of anticoagulation may decrease the risk of death requires further investigation. John Wiley and Sons Inc. 2018-07-17 /pmc/articles/PMC6165930/ /pubmed/30015405 http://dx.doi.org/10.1002/ehf2.12331 Text en © 2018 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of the European Society of Cardiology. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Original Research Articles
Di Tullio, Marco R.
Qian, Min
Thompson, John L.P.
Labovitz, Arthur J.
Mann, Douglas L.
Sacco, Ralph L.
Pullicino, Patrick M.
Freudenberger, Ronald S.
Teerlink, John R.
Graham, Susan
Lip, Gregory Y.H.
Levin, Bruce
Mohr, Jay P.
Buchsbaum, Richard
Estol, Conrado J.
Lok, Dirk J.
Ponikowski, Piotr
Anker, Stefan D.
Homma, Shunichi
Left atrial volume and cardiovascular outcomes in systolic heart failure: effect of antithrombotic treatment
title Left atrial volume and cardiovascular outcomes in systolic heart failure: effect of antithrombotic treatment
title_full Left atrial volume and cardiovascular outcomes in systolic heart failure: effect of antithrombotic treatment
title_fullStr Left atrial volume and cardiovascular outcomes in systolic heart failure: effect of antithrombotic treatment
title_full_unstemmed Left atrial volume and cardiovascular outcomes in systolic heart failure: effect of antithrombotic treatment
title_short Left atrial volume and cardiovascular outcomes in systolic heart failure: effect of antithrombotic treatment
title_sort left atrial volume and cardiovascular outcomes in systolic heart failure: effect of antithrombotic treatment
topic Original Research Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6165930/
https://www.ncbi.nlm.nih.gov/pubmed/30015405
http://dx.doi.org/10.1002/ehf2.12331
work_keys_str_mv AT ditulliomarcor leftatrialvolumeandcardiovascularoutcomesinsystolicheartfailureeffectofantithrombotictreatment
AT qianmin leftatrialvolumeandcardiovascularoutcomesinsystolicheartfailureeffectofantithrombotictreatment
AT thompsonjohnlp leftatrialvolumeandcardiovascularoutcomesinsystolicheartfailureeffectofantithrombotictreatment
AT labovitzarthurj leftatrialvolumeandcardiovascularoutcomesinsystolicheartfailureeffectofantithrombotictreatment
AT manndouglasl leftatrialvolumeandcardiovascularoutcomesinsystolicheartfailureeffectofantithrombotictreatment
AT saccoralphl leftatrialvolumeandcardiovascularoutcomesinsystolicheartfailureeffectofantithrombotictreatment
AT pullicinopatrickm leftatrialvolumeandcardiovascularoutcomesinsystolicheartfailureeffectofantithrombotictreatment
AT freudenbergerronalds leftatrialvolumeandcardiovascularoutcomesinsystolicheartfailureeffectofantithrombotictreatment
AT teerlinkjohnr leftatrialvolumeandcardiovascularoutcomesinsystolicheartfailureeffectofantithrombotictreatment
AT grahamsusan leftatrialvolumeandcardiovascularoutcomesinsystolicheartfailureeffectofantithrombotictreatment
AT lipgregoryyh leftatrialvolumeandcardiovascularoutcomesinsystolicheartfailureeffectofantithrombotictreatment
AT levinbruce leftatrialvolumeandcardiovascularoutcomesinsystolicheartfailureeffectofantithrombotictreatment
AT mohrjayp leftatrialvolumeandcardiovascularoutcomesinsystolicheartfailureeffectofantithrombotictreatment
AT buchsbaumrichard leftatrialvolumeandcardiovascularoutcomesinsystolicheartfailureeffectofantithrombotictreatment
AT estolconradoj leftatrialvolumeandcardiovascularoutcomesinsystolicheartfailureeffectofantithrombotictreatment
AT lokdirkj leftatrialvolumeandcardiovascularoutcomesinsystolicheartfailureeffectofantithrombotictreatment
AT ponikowskipiotr leftatrialvolumeandcardiovascularoutcomesinsystolicheartfailureeffectofantithrombotictreatment
AT ankerstefand leftatrialvolumeandcardiovascularoutcomesinsystolicheartfailureeffectofantithrombotictreatment
AT hommashunichi leftatrialvolumeandcardiovascularoutcomesinsystolicheartfailureeffectofantithrombotictreatment
AT leftatrialvolumeandcardiovascularoutcomesinsystolicheartfailureeffectofantithrombotictreatment